Abstract:AIMDendritomas formed by fusing cancer cells to dendritic cells have already been applied to clinical treatment trial of several types of cancers. Dendritic cells for the fusion in most trials and experiments were from blood monocytes in standard 7-d protocol culture, which requires 5-7 d of culture with granulocyte-macrophage-colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), followed by 2-3 d of activation with a combination of proinflammatory mediators such as tumor necrosis factoralpha (TNFalpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and prostaglandin E(2) (PGE(2)). One study showed that mature monocyte-derived dendritic cells could be obtained within 48 h of in vitro culture with the same protocol as standard 7-d culture and referred to as FastDCs. Here we aimed to fuse human hepatocellular carcinoma cell line HCCLM3 cells with mature monocyte-derived dendritic cells within 48 h of in vitro culture (FastDC).METHODSHCCLM3 cells were cultured in RPMI 1640 with 150 mL/L fetal calf serum (FCS). CD14+monocytes from healthy human peripheral blood were purified with MACS CD14 isolation kit and cultured in six-well plates in fresh complete DC medium containing RPMI-1640, 20 mL/L heat inactivated human AB serum, 2 mmol/L L-glutamine, 100 microg/mL gentamicin, 1 000 U/mL GM-CSF and 500 U/mL IL-4 for 24 h, then proinflammatory mediators such as TNFalpha (1 000 U/mL), IL-1beta (10 ng/mL), IL-6 (10 ng/mL) and PGE(2) (1 microg/mL) were supplemented for another 24 h, and thus mature FastDCs were generated. HCCLM3 cells and FastDCs were labeled with red fluorescent dye PKH26-GL and green fluorescent dye PKH67-GL respectively. After the red fluorescent-stained HCCLM3 cells were irradiated with 50 Gy, FastDCs and irradiated HCCLM3 cells were fused in 500 mL/L polyethylene glycol(PEG)+100 mL/L dimethyl sulfoxide (DMSO) to generate novel dendritomas. The FastDCs and novel dendritomas were immunostained with anti-CD80, anti-CD86, anti-CD83, anti-HLA-DR mAbs and analyzed by fluorescence-activated cell sorting (FACS). Novel dendritomas were nucleus-stained with Hoechst 33258 and analyzed by confocal laser scanning microscopy.RESULTSMature FastDCs with highly expressed surface markers CD80, CD86, CD83 and HLA-DR were generated within 48 h in vitro. Novel dendritomas with dual red-green fluorescence were constructed fast and successfully, and FACS analysis showed that the fusion efficiency was 24.27% and the novel dendritomas expressed the same activation markers as FastDCs. Confocal laser scanning microscopy analysis showed representative images of dendritomas.CONCLUSIONDendritomas can be formed fast with mature FastDCs from healthy human peripheral blood monocytes (PBMC) by incubation with GM-CSF and IL-4 for 24 h and by activation with proinflammatory mediators for an additional period of 24 h. Owing to shorter time required for in vitro DCs development, the generation of these novel dendritomas reduced labor and cost. This rapid method for formation of dendritomas may represent a new strategy for immunotherapy of hepatocellular carcinoma.

Rapidly Forming Hepatocellular Carcinoma Dendritomas by Fusing HCCLM3 and 48 H-Cultured DCs

A Novel, Rapid Strategy to Form Dendritomas from Human Dendritic Cells and Hepatocellular Carcinoma Cell Line HCCLM3 Cells Using Mature Dendritic Cells Derived from Human Peripheral Blood CD14+ Monocytes Within 48 Hours of in Vitro Culture.

[Inducing Hepatocellular Carcinoma-Specific Cytotoxic T Lymphocyte Response Using Formed by Fusion of FastDCs and Allogeneic Human Hepatocellular Carcinoma Cells].

[Establishment of Dendritomas by Fusion of Human Dendritic Cells with Human Hepatocellular Carcinoma Cell Line HLE Cells].

A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma

The study of dendritic cells derived from acute myeloid leukemia cells]

A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas

In Vitro Rapid Generation and Application of Mature Dendritic Cells from Peripheral Blood Cells of Patient with Melanoma

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Dendritomas Plays an Important Role in the Activation of Anti-Tumor Immune Responses

Dendritic Cells Pulsed with Α‐fetoprotein and Mutant P53 Fused Gene Induce Bi‐targeted Cytotoxic T Lymphocyte Response Against Hepatic Carcinoma

An Experimental Study on the Antitumor Effects Induced by Fusions of Dendritic Cells with NCI-H460 Lung Cancer Cells

Phenotypic and functional characteristics of dendritic cells derived from human peripheral blood monocytes

The Biological Characteristics of Dendritic Cells Derived in Vitro from Myelogeneous Leukemia Cells and Healthy Donor Cells.

Dendritic Cells Loaded with Ultrasound-Ablated Tumour Induce in Vivo Specific Antitumour Immune Responses

Induction of Specific Immune Response Against Hepatocellular Carcinoma by Human SLC and AFP Vector Transfected Dendritic Cells from CD34+ Hematopoietic Stem Cells

Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.

High Potency and Specific Anti-Tumor Immunoreaction Induced by Dendritic Cells and Superantigen

Polyriboin osinic polyribocytidylic acid induces rapid cultivation and maturation of dendritic cells from human peripheral blood in vitro

Generation and Functional Characterization of Dendritic Cell from Peripheral Mononuclear Cells of Patients with Solid Tumors in the Presence of Autologous Plasma

Facile Transformation of Murine and Human Primary Dendritic Cells into Robust and Modular Artificial Antigen‐Presenting Systems by Intracellular Hydrogelation